dsip danaher Dana Deasy Named CIO for

Vendor recommendations are not evidence-based

13% of the participants treated with the combined compound ended up discontinuing the trial, while 10% of the participants treated with semaglutide discontinued, however, none of the participants treated with cagrilintide discontinued their treatment plan indicating that cagrilintide was the most well tolerated by the study participants [2]

Based on available Phase 2 data, both agents share a side-effect profile broadly consistent with other medicines acting on metabolic hormone pathways, though the triple-agonist mechanism of retatrutide introduces some additional considerations

5 mg vials are typically used in shorter studies or for smaller animal models